Continuous Intravenous Administration of Live Genetically Modified Salmonella Typhimurium in Patients with Metastatic Melanoma

Journal of Immunotherapy

Volumn 26, Issue 2, 2003, Pages 179-180

  Heimann, David M ^a   Rosenberg, Steven A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFAZOLIN; SALMONELLOSIS VACCINE;

CANCER GROWTH; CHILL; CLINICAL TRIAL; DOSE RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEVER; HUMAN; HYPERURICEMIA; HYPOPHOSPHATEMIA; HYPOXIA; LETTER; MEDICAL LITERATURE; MELANOMA; METASTASIS; MIGRAINE; NONHUMAN; PRIORITY JOURNAL; TUMOR BIOPSY; VIRAL GENE THERAPY; VOMITING;

ADULT; BIOPSY, NEEDLE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOTHERAPY; INFUSIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; REMISSION INDUCTION; SALMONELLA TYPHIMURIUM; SALMONELLA VACCINES; SAMPLING STUDIES; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 0037336216     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-200303000-00011     Document Type: Letter

References (1)

1. Toso JF, Gill VI, Hwu P, et al. Phase I study of the intravenous administration of attenuated salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol. 2002; 20:142-152.